Allan Gibofsky

Summary

Affiliation: Hospital for Special Surgery
Country: USA

Publications

  1. doi request reprint Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries
    Allan Gibofsky
    Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    J Rheumatol 38:21-8. 2011
  2. ncbi request reprint Comparative effectiveness of current treatments for rheumatoid arthritis
    Allan Gibofsky
    Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY, USA
    Am J Manag Care 18:S303-14. 2012
  3. ncbi request reprint Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis
    Allan Gibofsky
    Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY, USA
    Am J Manag Care 18:S295-302. 2012
  4. ncbi request reprint American College of Rheumatology
    Allan Gibofsky
    Hospital for Special Surgery, New York, New York, USA
    J Med Assoc Ga 91:35-6. 2002
  5. ncbi request reprint Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study
    Allan Gibofsky
    Department of Medicine and Public Health, Weill Medical College of Cornell University, Hospital for Special Surgery, New York, New York 10021, USA
    Clin Ther 29:1071-85. 2007
  6. ncbi request reprint Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study
    Allan Gibofsky
    Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
    Curr Med Res Opin 22:169-83. 2006
  7. ncbi request reprint An analysis of recent antitrust issues affecting specialty practice: is dermatology immune?
    Allan Gibofsky
    Weill Medical College of Cornell University, New York, NY, USA
    Semin Cutan Med Surg 24:137-43. 2005
  8. ncbi request reprint Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial
    Allan Gibofsky
    Hospital for Special Surgery Weill Medical College of Cornell University, New York, New York 10021, USA
    Arthritis Rheum 48:3102-11. 2003
  9. doi request reprint Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry
    Joseph A Markenson
    Hospital for Special Surgery, New York, NY 10021, USA
    J Rheumatol 38:1273-81. 2011
  10. ncbi request reprint The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis
    Carla R Scanzello
    Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Curr Rheumatol Rep 10:49-56. 2008

Detail Information

Publications22

  1. doi request reprint Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries
    Allan Gibofsky
    Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    J Rheumatol 38:21-8. 2011
    ....
  2. ncbi request reprint Comparative effectiveness of current treatments for rheumatoid arthritis
    Allan Gibofsky
    Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY, USA
    Am J Manag Care 18:S303-14. 2012
    ....
  3. ncbi request reprint Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis
    Allan Gibofsky
    Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY, USA
    Am J Manag Care 18:S295-302. 2012
    ....
  4. ncbi request reprint American College of Rheumatology
    Allan Gibofsky
    Hospital for Special Surgery, New York, New York, USA
    J Med Assoc Ga 91:35-6. 2002
  5. ncbi request reprint Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study
    Allan Gibofsky
    Department of Medicine and Public Health, Weill Medical College of Cornell University, Hospital for Special Surgery, New York, New York 10021, USA
    Clin Ther 29:1071-85. 2007
    ..This study compared the efficacy and tolerability of the cyclooxygenase-2-selective inhibitor valdecoxib with the nonselective NSAID naproxen and with placebo in treating severe rheumatoid arthritis (RA)...
  6. ncbi request reprint Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study
    Allan Gibofsky
    Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
    Curr Med Res Opin 22:169-83. 2006
    ..RADIUS provides a snapshot of use patterns, effectiveness, and safety of DMARDs, biologics, and combination therapies used to manage RA in clinical practice...
  7. ncbi request reprint An analysis of recent antitrust issues affecting specialty practice: is dermatology immune?
    Allan Gibofsky
    Weill Medical College of Cornell University, New York, NY, USA
    Semin Cutan Med Surg 24:137-43. 2005
    ..Although recent case law has involved actions undertaken by physicians in other specialties of Medicine (e.g. oncology) the activities reviewed will likely be applicable to Dermatologists as well...
  8. ncbi request reprint Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial
    Allan Gibofsky
    Hospital for Special Surgery Weill Medical College of Cornell University, New York, New York 10021, USA
    Arthritis Rheum 48:3102-11. 2003
    ..To compare the efficacy of the cyclooxygenase 2 (COX-2)-specific inhibitors celecoxib and rofecoxib in treating the signs and symptoms of osteoarthritis (OA)...
  9. doi request reprint Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry
    Joseph A Markenson
    Hospital for Special Surgery, New York, NY 10021, USA
    J Rheumatol 38:1273-81. 2011
    ..To evaluate persistence with anti-tumor necrosis factor (TNF) therapy and predictors of discontinuation in patients with rheumatoid arthritis (RA)...
  10. ncbi request reprint The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis
    Carla R Scanzello
    Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Curr Rheumatol Rep 10:49-56. 2008
    ..This review highlights the evidence behind the effectiveness of other, non-NSAID pharmacologic options in the treatment of pain and inflammation in osteoarthritis...
  11. doi request reprint A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry
    Jeffrey D Greenberg
    New York University Hospital for Joint Diseases, Department of Rheumatology, 301 East 17th Street, Suite 1410, New York, NY 10003, USA
    Ann Rheum Dis 71:1134-42. 2012
    ..To compare the effectiveness of anti-tumour necrosis factor (TNF) agents in biologically naive and 'switched' rheumatoid arthritis (RA) patients...
  12. ncbi request reprint Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases
    Allan Gibofsky
    Weill Medical College of Cornell University, New York, New York, USA
    J Hypertens Suppl 20:S25-30. 2002
    ..This presentation reviews the mechanism of action of these agents, the clinical studies showing their effectiveness for treatment of arthritis, and the gastrointestinal side effect profiles compared with conventional NSAIDs...
  13. ncbi request reprint Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C
    Timothy B Niewold
    Hospital for Special Surgery, New York, NY, USA
    Arthritis Rheum 54:2335-7. 2006
  14. doi request reprint Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic
    Allan Gibofsky
    Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Am J Ther 15:241-55. 2008
    ..The purpose of this review is to highlight the efficacy and safety of extended-release opioid analgesics utilized in the management plan of chronic pain due to osteoarthritis...
  15. ncbi request reprint If I am not for myself, who will be for me?
    Allan Gibofsky
    Weill Medical College of Cornell University and Hospital for Special Surgery, New York, New York, USA
    Arthritis Rheum 48:869-72. 2003
  16. doi request reprint Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
    Ora Singer
    Department of Rheumatology, Medical College of Georgia, Augusta, Georgia, USA
    Curr Opin Rheumatol 23:288-92. 2011
    ..To review the recent efficacy and safety data comparing methotrexate (MTX) and leflunomide (LEF) monotherapy, in combination with biologic therapies and in combination with each other...
  17. ncbi request reprint The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis
    Carla R Scanzello
    Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
    Curr Pain Headache Rep 11:415-22. 2007
    ..This review highlights the evidence behind the effectiveness of other, non-NSAID pharmacologic options in the treatment of pain and inflammation in osteoarthritis...
  18. ncbi request reprint Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry
    Arthur L Weaver
    University of Nebraska Medical Center, Omaha, NE, USA
    Curr Med Res Opin 22:185-98. 2006
    ..To evaluate the effectiveness of select biologics, methotrexate (MTX), and other disease-modifying anti-rheumatic drugs (DMARDs) in the management of adult rheumatoid arthritis (RA) in routine clinical practice...
  19. doi request reprint The role of drug and disease registries in rheumatic disease epidemiology
    Joel M Kremer
    Albany Medical College, 1367 Washington Avenue, Albany, NY 12206, USA
    Curr Opin Rheumatol 20:123-30. 2008
    ..This review highlights the present state of efforts at registry implementation which exist internationally. These efforts are contrasted with those in the USA...
  20. ncbi request reprint Pay for performance in rheumatology: will we get the carrot or the stick?
    Allan Gibofsky
    Arthritis Rheum 59:1203-6. 2008
  21. ncbi request reprint Improving survival in inflammatory rheumatic diseases: a neglected goal?
    Theodore Pincus
    Division of Rheumatology and Immunology, Vanderbilt University School of Medicine, 203 Oxford House, Box 5, Nashville, TN 37232 4500, USA
    Curr Rheumatol Rep 8:401-3. 2006
  22. ncbi request reprint Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists
    Theodore Pincus
    Arthritis Rheum 46:851-4. 2002